Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

VYNE Therapeutics (VYNE) Cost of Revenue (2020 - 2021)

VYNE Therapeutics (VYNE) has disclosed Cost of Revenue for 2 consecutive years, with $903000.0 as the latest value for Q4 2021.

  • For the quarter ending Q4 2021, Cost of Revenue rose 69.1% year-over-year to $903000.0, compared with a TTM value of $3.3 million through Dec 2021, up 140.52%, and an annual FY2021 reading of $3.3 million, up 140.52% over the prior year.
  • Cost of Revenue was $903000.0 for Q4 2021 at VYNE Therapeutics, down from $1.0 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $1.0 million in Q3 2021 and bottomed at $216000.0 in Q2 2020.